OssDsign is launching a new size of OssDsign Catalyst nanosynthetic bone graft. The additional volume option of 1 cc completes the existing product range of 10, 5 and 2,5 ccs, and broadens access to new procedures in both cervical spine and smaller extremities. The product is expected to launch in 1Q23.
A complete size range of OssDsign Catalyst lends the company competitive strength in hospital approval processes and allows for deeper usage in already approved hospitals. Further, the 1cc size allows the company to target Ambulatory Surgery Centers.
OssDsign Catalyst stimulates the formation of healthy bone tissue in spinal fusion. The graft comprises a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue in the body.
“We are very happy to extend our offering and further increase our commercial opportunity, as our new smaller size of OssDsign Catalyst gives access to additional procedures. It also means we can now offer a complete and more competitive size range to both existing users and new potential hospitals,” says Morten Henneveld, CEO.
OssDsign is launching a new size of OssDsign Catalyst nanosynthetic bone graft. The additional volume option of 1 cc completes the existing product range of 10, 5 and 2,5 ccs, and broadens access to new procedures in both cervical spine and smaller extremities. The product is expected to launch in 1Q23.
A complete size range of OssDsign...
OssDsign is launching a new size of OssDsign Catalyst nanosynthetic bone graft. The additional volume option of 1 cc completes the existing product range of 10, 5 and 2,5 ccs, and broadens access to new procedures in both cervical spine and smaller extremities. The product is expected to launch in 1Q23.
A complete size range of OssDsign Catalyst lends the company competitive strength in hospital approval processes and allows for deeper usage in already approved hospitals. Further, the 1cc size allows the company to target Ambulatory Surgery Centers.
OssDsign Catalyst stimulates the formation of healthy bone tissue in spinal fusion. The graft comprises a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue in the body.
“We are very happy to extend our offering and further increase our commercial opportunity, as our new smaller size of OssDsign Catalyst gives access to additional procedures. It also means we can now offer a complete and more competitive size range to both existing users and new potential hospitals,” says Morten Henneveld, CEO.
Copy to clipboard 
